David J. Zelinger

Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate

Larry W. Moreland, Parks W. Pratt, Maureen D. Mayes et al. · Arthritis & Rheumatism · 1995 · 109 citations

Life Sciences, Immunology, Pharmacotherapy +16

A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency.

Ali Keshavarzian, Lloyd Mayer, Bruce Salzberg et al. · PubMed · 2007 · 27 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +16

Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study

Ben A. van Hout, Lee Bowman, David J. Zelinger et al. · American Heart Journal · 1998 · 24 citations

Medicine, Cardiology, Pharmacotherapy +17

Early Serum Infliximab Trough Level, Clinical Disease Activity and CRP as Markers of Sustained Benefit of Infliximab Treatment in Crohnʼs Disease: A Post-hoc Analysis of the ACCENT1 Trial

Freddy Cornillie, Stephen B. Hanauer, Robert H. Diamond et al. · The American Journal of Gastroenterology · 2011 · 11 citations

Veterinary Medicine, Immunology, Pharmacotherapy +17